The addition of TMZ increased the overall survival (OS) from 7.7 to 13.5 months and from 7.9 to 10.0 months in the GBM patients with methylated and non-methylated O6-methylguanine-DNA methyl transferase (MGMT) respectively [3, 4]; however survival remains very poor. Here, MGMT is linked to glioblastoma.